Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy
- PMID: 12457792
- DOI: 10.1016/S0140-6736(02)11606-0
Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy
Abstract
Renal allograft recipients generally need to take several immunosuppressive agents for life. Calcineurin inhibitors and glucocorticosteroids are the mainstays of most regimens but have undesirable chronic effects. We postulated that aggressive T-cell depletion combined with the newer immunosuppressant sirolimus would permit transplantation without multidrug treatment. We therefore tested T-cell depletion with rabbit antithymocyte globulin followed by sirolimus monotherapy in 12 patients in an open-label study. This approach was tolerated well, and all patients achieved excellent renal function, and most did not need chronic steroid treatment or calcineurin inhibitors. Rejection was typically correlated with low concentrations of sirolimus, indicating continued dependence on maintenance immunosuppression.
Comment in
-
Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy.Lancet. 2003 Mar 15;361(9361):969; author reply 969-70. doi: 10.1016/S0140-6736(03)12752-3. Lancet. 2003. PMID: 12648994 No abstract available.
Similar articles
-
Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.Nephrology (Carlton). 2008 Feb;13(1):80-6. doi: 10.1111/j.1440-1797.2007.00866.x. Nephrology (Carlton). 2008. PMID: 18199109
-
Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy.Lancet. 2003 Mar 15;361(9361):969; author reply 969-70. doi: 10.1016/S0140-6736(03)12752-3. Lancet. 2003. PMID: 12648994 No abstract available.
-
Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.Int Immunopharmacol. 2006 Dec 20;6(13-14):1973-6. doi: 10.1016/j.intimp.2006.09.013. Epub 2006 Oct 10. Int Immunopharmacol. 2006. PMID: 17161350 Clinical Trial.
-
The evolving role of sirolimus in renal transplantation.QJM. 2003 Jun;96(6):401-9. doi: 10.1093/qjmed/hcg072. QJM. 2003. PMID: 12788958 Review. No abstract available.
-
Maintenance immunosuppression in renal transplantation.Curr Opin Pharmacol. 2013 Aug;13(4):662-71. doi: 10.1016/j.coph.2013.05.004. Epub 2013 May 31. Curr Opin Pharmacol. 2013. PMID: 23731524 Review.
Cited by
-
Benefit-risk assessment of sirolimus in renal transplantation.Drug Saf. 2005;28(2):153-81. doi: 10.2165/00002018-200528020-00006. Drug Saf. 2005. PMID: 15691225 Review.
-
Induction therapy in renal transplantation : an overview of current developments.Drugs. 2007;67(18):2667-80. doi: 10.2165/00003495-200767180-00003. Drugs. 2007. PMID: 18062717 Review.
-
DNA methylation predicts infection risk in kidney transplant recipients.Life Sci Alliance. 2025 May 5;8(7):e202403124. doi: 10.26508/lsa.202403124. Print 2025 Jul. Life Sci Alliance. 2025. PMID: 40324822 Free PMC article.
-
Regulation of immune responses by mTOR.Annu Rev Immunol. 2012;30:39-68. doi: 10.1146/annurev-immunol-020711-075024. Epub 2011 Nov 29. Annu Rev Immunol. 2012. PMID: 22136167 Free PMC article. Review.
-
Alemtuzumab as Antirejection Therapy: T Cell Repopulation and Cytokine Responsiveness.Transplant Direct. 2016 May 25;2(6):e83. doi: 10.1097/TXD.0000000000000595. eCollection 2016 Jun. Transplant Direct. 2016. PMID: 27500273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical